Identification of prognostic factors for plerixafor-based hematopoietic stem cell mobilization

Grzegorz W. Basak, Ozren Jaksic, Zdenek Koristek, G. Mikala, Jiri Mayer, T. Masszi, Boris Labar, Wieslaw Wiktor-Jedrzejczak

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

The introduction of plerixafor has enabled successful collection of stem cells in the majority of patients with lymphoma or myeloma in whom previous attempts at mobilization have failed. However, a proportion of patients have been shown to be resistant to this mobilization regimen. To identify the factors that impair stem cell mobilization and collection with plerixafor, we reviewed the data for 197 patients who had undergone mobilization with plerixafor and granulocyte-colony stimulating factor in Central Europe. Predictors of mobilization failure were evaluated using logistic regression analysis. Among the 197 patients mobilized, the target of ≥2.0 × 106 CD34+ cells/kg was collected from 133 (67.5%). Our analysis revealed that previous treatment with lenalidomide, bortezomib, melphalan, radiotherapy, or autologous stem cell transplantation and regimen of plerixafor use in combination with chemotherapy had no significant effect on the efficiency of collection. In contrast, an age ≥65 years (odds ratio 0.331, 95% CI: 0.112-0.977, P <0.05), a diagnosis of non-Hodgkin's lymphoma (odds ratio 0.277, 95% CI: 0.124-0.622, P <0.01), and treatment with ≥ four chemotherapy regimens (odds ratio 0.366, 95% CI: 0.167-0.799, P <0.05) were associated significantly with failed mobilization. The rate of successful mobilizations was decreased in patients treated with purine analogues (odds ratio 0.323, 95% CI: 0.096-1.094, P = 0.07) but increased in female patients (odds ratio 1.961, CI: 0.943-4.080, P = 0.07). Patients who are characterized by the above negative features could benefit potentially from further improvement in the mobilization strategy.

Original languageEnglish
Pages (from-to)550-553
Number of pages4
JournalAmerican Journal of Hematology
Volume86
Issue number7
DOIs
Publication statusPublished - Jul 2011

Fingerprint

Hematopoietic Stem Cell Mobilization
Odds Ratio
Melphalan
Stem Cell Transplantation
Granulocyte Colony-Stimulating Factor
JM 3100
Combination Drug Therapy
Non-Hodgkin's Lymphoma
Lymphoma
Radiotherapy
Stem Cells
Logistic Models
Regression Analysis
Drug Therapy
Therapeutics

ASJC Scopus subject areas

  • Hematology

Cite this

Identification of prognostic factors for plerixafor-based hematopoietic stem cell mobilization. / Basak, Grzegorz W.; Jaksic, Ozren; Koristek, Zdenek; Mikala, G.; Mayer, Jiri; Masszi, T.; Labar, Boris; Wiktor-Jedrzejczak, Wieslaw.

In: American Journal of Hematology, Vol. 86, No. 7, 07.2011, p. 550-553.

Research output: Contribution to journalArticle

Basak, Grzegorz W. ; Jaksic, Ozren ; Koristek, Zdenek ; Mikala, G. ; Mayer, Jiri ; Masszi, T. ; Labar, Boris ; Wiktor-Jedrzejczak, Wieslaw. / Identification of prognostic factors for plerixafor-based hematopoietic stem cell mobilization. In: American Journal of Hematology. 2011 ; Vol. 86, No. 7. pp. 550-553.
@article{c90f4df4a75844ec8aede22c1c90fe93,
title = "Identification of prognostic factors for plerixafor-based hematopoietic stem cell mobilization",
abstract = "The introduction of plerixafor has enabled successful collection of stem cells in the majority of patients with lymphoma or myeloma in whom previous attempts at mobilization have failed. However, a proportion of patients have been shown to be resistant to this mobilization regimen. To identify the factors that impair stem cell mobilization and collection with plerixafor, we reviewed the data for 197 patients who had undergone mobilization with plerixafor and granulocyte-colony stimulating factor in Central Europe. Predictors of mobilization failure were evaluated using logistic regression analysis. Among the 197 patients mobilized, the target of ≥2.0 × 106 CD34+ cells/kg was collected from 133 (67.5{\%}). Our analysis revealed that previous treatment with lenalidomide, bortezomib, melphalan, radiotherapy, or autologous stem cell transplantation and regimen of plerixafor use in combination with chemotherapy had no significant effect on the efficiency of collection. In contrast, an age ≥65 years (odds ratio 0.331, 95{\%} CI: 0.112-0.977, P <0.05), a diagnosis of non-Hodgkin's lymphoma (odds ratio 0.277, 95{\%} CI: 0.124-0.622, P <0.01), and treatment with ≥ four chemotherapy regimens (odds ratio 0.366, 95{\%} CI: 0.167-0.799, P <0.05) were associated significantly with failed mobilization. The rate of successful mobilizations was decreased in patients treated with purine analogues (odds ratio 0.323, 95{\%} CI: 0.096-1.094, P = 0.07) but increased in female patients (odds ratio 1.961, CI: 0.943-4.080, P = 0.07). Patients who are characterized by the above negative features could benefit potentially from further improvement in the mobilization strategy.",
author = "Basak, {Grzegorz W.} and Ozren Jaksic and Zdenek Koristek and G. Mikala and Jiri Mayer and T. Masszi and Boris Labar and Wieslaw Wiktor-Jedrzejczak",
year = "2011",
month = "7",
doi = "10.1002/ajh.22038",
language = "English",
volume = "86",
pages = "550--553",
journal = "American Journal of Hematology",
issn = "0361-8609",
publisher = "Wiley-Liss Inc.",
number = "7",

}

TY - JOUR

T1 - Identification of prognostic factors for plerixafor-based hematopoietic stem cell mobilization

AU - Basak, Grzegorz W.

AU - Jaksic, Ozren

AU - Koristek, Zdenek

AU - Mikala, G.

AU - Mayer, Jiri

AU - Masszi, T.

AU - Labar, Boris

AU - Wiktor-Jedrzejczak, Wieslaw

PY - 2011/7

Y1 - 2011/7

N2 - The introduction of plerixafor has enabled successful collection of stem cells in the majority of patients with lymphoma or myeloma in whom previous attempts at mobilization have failed. However, a proportion of patients have been shown to be resistant to this mobilization regimen. To identify the factors that impair stem cell mobilization and collection with plerixafor, we reviewed the data for 197 patients who had undergone mobilization with plerixafor and granulocyte-colony stimulating factor in Central Europe. Predictors of mobilization failure were evaluated using logistic regression analysis. Among the 197 patients mobilized, the target of ≥2.0 × 106 CD34+ cells/kg was collected from 133 (67.5%). Our analysis revealed that previous treatment with lenalidomide, bortezomib, melphalan, radiotherapy, or autologous stem cell transplantation and regimen of plerixafor use in combination with chemotherapy had no significant effect on the efficiency of collection. In contrast, an age ≥65 years (odds ratio 0.331, 95% CI: 0.112-0.977, P <0.05), a diagnosis of non-Hodgkin's lymphoma (odds ratio 0.277, 95% CI: 0.124-0.622, P <0.01), and treatment with ≥ four chemotherapy regimens (odds ratio 0.366, 95% CI: 0.167-0.799, P <0.05) were associated significantly with failed mobilization. The rate of successful mobilizations was decreased in patients treated with purine analogues (odds ratio 0.323, 95% CI: 0.096-1.094, P = 0.07) but increased in female patients (odds ratio 1.961, CI: 0.943-4.080, P = 0.07). Patients who are characterized by the above negative features could benefit potentially from further improvement in the mobilization strategy.

AB - The introduction of plerixafor has enabled successful collection of stem cells in the majority of patients with lymphoma or myeloma in whom previous attempts at mobilization have failed. However, a proportion of patients have been shown to be resistant to this mobilization regimen. To identify the factors that impair stem cell mobilization and collection with plerixafor, we reviewed the data for 197 patients who had undergone mobilization with plerixafor and granulocyte-colony stimulating factor in Central Europe. Predictors of mobilization failure were evaluated using logistic regression analysis. Among the 197 patients mobilized, the target of ≥2.0 × 106 CD34+ cells/kg was collected from 133 (67.5%). Our analysis revealed that previous treatment with lenalidomide, bortezomib, melphalan, radiotherapy, or autologous stem cell transplantation and regimen of plerixafor use in combination with chemotherapy had no significant effect on the efficiency of collection. In contrast, an age ≥65 years (odds ratio 0.331, 95% CI: 0.112-0.977, P <0.05), a diagnosis of non-Hodgkin's lymphoma (odds ratio 0.277, 95% CI: 0.124-0.622, P <0.01), and treatment with ≥ four chemotherapy regimens (odds ratio 0.366, 95% CI: 0.167-0.799, P <0.05) were associated significantly with failed mobilization. The rate of successful mobilizations was decreased in patients treated with purine analogues (odds ratio 0.323, 95% CI: 0.096-1.094, P = 0.07) but increased in female patients (odds ratio 1.961, CI: 0.943-4.080, P = 0.07). Patients who are characterized by the above negative features could benefit potentially from further improvement in the mobilization strategy.

UR - http://www.scopus.com/inward/record.url?scp=79959354700&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79959354700&partnerID=8YFLogxK

U2 - 10.1002/ajh.22038

DO - 10.1002/ajh.22038

M3 - Article

C2 - 21674573

AN - SCOPUS:79959354700

VL - 86

SP - 550

EP - 553

JO - American Journal of Hematology

JF - American Journal of Hematology

SN - 0361-8609

IS - 7

ER -